Journals / European Journal of Rheumatology / 2014 / Cilt: 1 - Sayı: 3

Nötrofil lenfosit oranı ankilozan spondilit için anti-tümör nekroz faktörü (TNF) ilaçları başlamış hastalarda hastalık aktivitesinin belirlenmesinde değerli bir belirteç olabilir

Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis

Pages
101–105
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

NLR was found with a mathematical calculation of the ratio of neutrophils with lymphocytes.Results: The mean NLR value of the control group and patients was 1.90±0.89 and 2.67±1.17, respectively (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Neutrophil lymphocyte ratio (NLR) has emerged as a valuable and reliable method for follow-up of systemic inflammatory disease.
📊
Key Findings & Data:We herein aimed to evaluate the role of NLR in the clinical follow-up of inflammation and also to compare its relationship with other measures, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).
💡
Conclusion & Impact:NLR was found with a mathematical calculation of the ratio of neutrophils with lymphocytes.Results: The mean NLR value of the control group and patients was 1.90±0.89 and 2.67±1.17, respectively (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Neutrophil lymphocyte ratio (NLR) has emerged as a valuable and reliable method for follow-up of systemic inflammatory disease. We herein aimed to evaluate the role of NLR in the clinical follow-up of inflammation and also to compare its relationship with other measures, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Material and Methods: A total of 35 active ankylosing spondylitis (AS) and 38 healthy volunteers were included in the study. The patient group was enrolled for treatment with one anti-tumor necrosis factor (TNF) drug. Total blood count, ESR, CRP, and BASDAI score were obtained before and 3 months following the treatment. NLR was found with a mathematical calculation of the ratio of neutrophils with lymphocytes.Results: The mean NLR value of the control group and patients was 1.90±0.89 and 2.67±1.17, respectively (p

Özet

Amaç: Nötrofil lenfosit oranı (NLO) sistemik inflamatuvar hastalık takibi için değerli ve güvenilir bir yöntem olarak ortaya çıkmıştır. Biz burada inflamasyonun klinik takibinde NLO'nun rolünü değerlendirmeyi ve eritrosit sedimentasyon hızı (ESR), C-reaktif protein (CRP) ve Bath Ankilozan Spondilit Hastalık Aktivite İndeksi (BASDAI) gibi ölçümlerle NLO'nun ilişkisini karşılaştırmayı amaçladık. Materyal ve Metot: Çalışmaya 35 aktif ankilozan spondilit (AS) hastası ve 38 sağlıklı gönüllü dahil edildi. Hasta grubuna bir anti-tümör nekroz faktörü (TNF) ilacıyla tedavi edilecek hastalar alındı. Tam kan sayımı, ESR, CRP seviyesi ve BASDAI skoru tedavi öncesi ve tedaviden 3 ay sonra elde edildi. NRO, nötrofillerin lenfositlere oranı olarak matematiksel hesaplamayla belirlendi. Bulgular: Kontrol ve hasta gruplarının ortalama NLO değerleri sırasıyla 1.90±0.89 ve 2.67±1.17 idi (p

🔖

Cite This Article

ORUÇOĞLU, N., DALKILIÇ, E., ÖKSÜZ, M. F., TUFAN, A. N., DOĞAN, A., COŞKUN, B. N., ERMURAT, S., PEHLİVAN, Y. (2022). Nötrofil lenfosit oranı ankilozan spondilit için anti-tümör nekroz faktörü (TNF) ilaçları başlamış hastalarda hastalık aktivitesinin belirlenmesinde değerli bir belirteç olabilir. European Journal of Rheumatology, Cilt: 1 - Sayı: 3, 101–105. https://ajindex.com/articles/650449

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Gensler L. Clinical Features of Ankylosing Spon- dylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheuma- tology, 5th edition, Philadelphia, PA: USA; 2011. p. 1129-34. [CrossRef] Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the Unit- ed States. Am J Med Sci 2013; 345: 431-6. [CrossRef] Onen F, Akar S, Birlik M, Sari I, Khan MA, Gurler O, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008; 35: 305-9.
  2. Saxena A, Cronstein BN. Acute Phase Reactants and the Concept of Inflammation. In: Firestein GS et al, editors. Kelley's Textbook of Rheuma- tology, 9th edition. Philadelphia, PA: USA; 2013. p. 818-29. [CrossRef] Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E, et al. Clinical relevance of C-reactive protein in axial involvement of anky- losing spondylitis. J Rheumatol 1999; 26: 971-4. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Rel- ative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26: 980-4.
  3. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to de- fining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activitiy index. J Rheumatol 1994; 21: 2286-91.
  4. Akkoc Y, Karatepe AG, Akar S, Kirazlı Y, Akkoc N. A Turkish version of the Bath Ankylosing Spon- dylitis Disease Activity Index: reliability and va- lidity. Rheumatol Int 2005; 25: 280-4. [CrossRef] Braun J, Heijde van der D, Dougados M, Emery P, Khan MA, Sieper J, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis 2002; 61: 19-23.
  5. Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for an- kylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in pa- tients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985; 24: 242-9. [CrossRef] Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 1999; 57: 16-21.
  6. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a mea- sure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med 2012; 5: 2. [CrossRef] Guthrie GJ, Charles KA, Roxburgh CS, Horgan